Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

discovered and initially

developed by Roche; EntreMed has an exclusive worldwide license to

develop and commercialize the drug.

-- MKC-1 is currently in multiple Phase 1 and Phase 2 clinical trials,

including metastatic breast cancer (MBC), non-small cell lung cancer

(NSCLC), hematological cancers, ovarian and endometrial cancer, and

pancreatic cancer. Milestones for MKC-1 in 2008 include reporting

results for the single agent MKC-1 MBC study (2Q08); presentation of

interim data for MKC-1/Alimta combination study in NSCLC (2Q08);

presentation of Phase 1 data for MKC-1 in hematological cancers (2H08);

initiation of a Phase 1 MKC-1 continuous dosing study (2Q08); and

presentation of interim data for a Phase 2 study in pancreatic cancer

(4Q08).

-- ENMD-1198 is a potent, orally-active, antimitotic agent discovered at

EntreMed that causes cell cycle arrest and apoptosis in tumor cells.

ENMD-1198 has shown pronounced antitumor activity and survival

increases in multiple preclinical models, including a substantial

decrease in tumor cell proliferation and angiogenesis in a breast

cancer model; synergistic effects in combination with vincristine that

prolonged survival in preclinical leukemia models; and a three-fold

increase in survival compared to standard-of-care Cisplatin in a

preclinical NSCLC model.

-- A Phase 1b dose-escalation clinical trial is currently underway to

evaluate ENMD-1198 in patients with refractory solid tumors. Completion

of the study is expected around mid-2008 with a further trial expected

in the second half of 2008. ENMD-1198 milestones for 2008 include

completion of Phase 1b enrollment (2Q/3Q08); initiation of an expanded

Phase 1 or Phase 2 trial (3Q/4Q08); and the reporting of data for the

Phase 1b clinical
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 ... addition of the "Spectroscopy Equipment and ... report to their offering. ... Spectroscopy Equipment and Accessories in US$ Thousands ... (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a life ... products for advanced microarray diagnostics, today announced it will ... at 2:00 pm ET.  During the ... brief review of SQI,s recent commercialization progress and then ... veteran recently appointed to the Board of Directors of ...
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... NEW YORK, Sept. 7 Richard Gabriel, Chief,Executive ... DNAG),( http://www.dnaprint.com ) will be featured in an ... to take place on September 10 at 11,a.m. ... http://www.wallst.net by 8 p.m.,EDT on September 10. ...
... Inc. (Nasdaq: HGSI ) announced today that its ... New York will be webcast,and may be accessed at ... A member of Human Genome Sciences, senior management ... September 11, 2007 at 4:00 pm,Eastern Time. Investors ...
... Appeared More Effective Than rituximab ... in a ... GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing ... in a pre-clinical study. The CD20,antibodies were incubated with tumor ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2Genmab Announces Encouraging Preclinical Data for ofatumumab 2
(Date:8/19/2014)... August 19, 2014A new ovoid structure discovered in the ... contains a variety of minerals, and shows evidence of ... melting of the permafrost and mixing of surface and ... range of analytical studies to determine the origin of ... how this ovoid formed, point to the most likely ...
(Date:8/19/2014)... analyzed concentrations of African dust transported to South ... spring. These research findings offer new insight on ... of African dust, including the climate change-induced human ... increased African dust emissions in the coming decades., ... School of Marine and Atmospheric Science and colleagues ...
(Date:8/19/2014)... This news release is available in French . ... Stand: balancing the BENEFITS and RISKS of physical activity ... a stand on the promotion of childhood physical activity ... Applied Physiology, Nutrition, and Metabolism ( APNM ... of knowledge in the area of risk of physical ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... may trigger the development of schizophrenia and other bipolar ... Faculty of Biological Sciences (UK) has shown that the ... these disorders by affecting the production of dopamine - ... aspects of movement, cognition and behaviour. Toxoplasmosis, which ...
... in genes which can result in changes in the ... associated with susceptibility to common diseases. In a new ... the Association for Psychological Science, psychologist Tina B. Lonsdorf ... and the University of Greifswald in Germany examined the ...
... fluoride (SO 2 F 2 ), a gas commonly used to ... that remains in the atmosphere about 36 years, six to 10 ... by Jens Mhle, an atmospheric chemist at Scripps Institution of Oceanography, ... the gas rose at a rate of 4 to 6 percent ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2Termite killer lingers as a potent greenhouse gas 2Termite killer lingers as a potent greenhouse gas 3
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: